The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

J Thorac Oncol

*Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa, University of Barcelona, and CIBERES Lung Cancer Group, Terrassa, Barcelona, Spain; †Cancer Research And Biostatistics, Seattle, Washington; ‡Department of Radiotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia; §Department of Thoracic Surgery, Samsung Medical Center, Seoul, South Korea; ‖Department of Thoracic Surgery, Hospital Británico, Buenos Aires, Argentina; ¶Department of Thoracic Surgery, Cleveland Clinic, Cleveland, Ohio; #Department of Thoracic Surgery, Juntendo University, Tokyo, Japan; **Department of Internal Medicine and Pulmonology, Mayo Clinic, Rochester, Minnesota; ††Department of Pathology, Sloan-Kettering Cancer Center, New York, New York; ‡‡Guangdong Lung Cancer Institute, Guangdong, General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China; and §§Members of the IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions are listed in the Appendix.

Published: July 2015

Introduction: An international database was collected to inform the 8 edition of the anatomic classification of lung cancer. The present analyses concern its primary tumor (T) component.

Methods: From 1999 to 2010, 77,156 evaluable patients, 70,967 with non-small-cell lung cancer, were collected; and 33,115 had either a clinical or a pathological classification, known tumor size, sufficient T information, and no metastases. Survival was measured from date of diagnosis or surgery for clinically and pathologically staged tumors. Tumor-size cutpoints were evaluated by the running log-rank statistics. T descriptors were evaluated in a multivariate Cox regression analysis adjusted for age, gender, histological type, and geographic region.

Results: The 3-cm cutpoint significantly separates T1 from T2. From 1 to 5 cm, each centimeter separates tumors of significantly different prognosis. Prognosis of tumors greater than 5 cm but less than or equal to 7 cm is equivalent to T3, and that of those greater than 7 cm to T4. Bronchial involvement less than 2 cm from carina, but without involving it, and total atelectasis/pneumonitis have a T2 prognosis. Involvement of the diaphragm has a T4 prognosis. Invasion of the mediastinal pleura is a descriptor seldom used.

Conclusions: Recommended changes are as follows: to subclassify T1 into T1a (≤1 cm), T1b (>1 to ≤2 cm), and T1c (>2 to ≤3 cm); to subclassify T2 into T2a (>3 to ≤4 cm) and T2b (>4 to ≤5 cm); to reclassify tumors greater than 5 to less than or equal to 7 cm as T3; to reclassify tumors greater than 7 cm as T4; to group involvement of main bronchus as T2 regardless of distance from carina; to group partial and total atelectasis/pneumonitis as T2; to reclassify diaphragm invasion as T4; and to delete mediastinal pleura invasion as a T descriptor.

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000559DOI Listing

Publication Analysis

Top Keywords

lung cancer
16
tumors greater
12
classification lung
8
equal 7 cm
8
greater 7 cm
8
total atelectasis/pneumonitis
8
mediastinal pleura
8
reclassify tumors
8
tumors
5
iaslc lung
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!